Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Mid-Cap · Voya

Nomura Mid Cap Income Opportunities Fund Class C (IVOCX)

Ticker IVOCX · · Holdings as of Jun 30, 2026

Expense ratio
1.82%$182/yr per $10k
5-yr return
+7.3%annualized
1-yr return
+6.4%as of Dec 2025
Net assets
$716.4Mall share classes
Holdings
39

Bottom line

Is IVOCX a good fund? The bottom line

IVOCX is the Class C share class of Nomura Mid Cap Income Opportunities Fund, an actively managed mid-cap mutual fund from Voya.

Its expense ratio is 1.82% — about $182 a year on every $10,000 invested, more expensive than 93% of mid-cap funds we track.

It returned +6.4% over one year, +7.3% a year over five years, +9.5% a year over ten (as of Dec 31, 2025, per its prospectus).

With $716 million in net assets and 39 holdings, its largest position is Arthur J. Gallagher & Company (3.0%) and the top 10 make up 29.2% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.82%)
  • 12b-1 marketing fee of 1% a year

Updated Nov 19, 2026

What IVOCX invests in

Nomura Mid Cap Income Opportunities Fund seeks to provide total return through a combination of current income and capital appreciation.

Nomura Mid Cap Income Opportunities Fund seeks to achieve its objective by investing primarily in a diversified portfolio of income-producing common stocks of mid-capitalization companies that the Manager believes demonstrate favorable prospects for total return. Under normal circumstances, the Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the securities of mid-capitalization companies (80% policy). For purposes of the Funds 80% policy, mid-capitalization companies are companies with market capitalizations similar to those of issuers included in the Russell Midcap Index over the last 13 months at the time of acquisition. As of June 30, 2026, this range of market capitalizations was between approximately $717 million and $92.6 billion. The Fund focuses primarily on mid-capitalization companies that the Manager believes have…

From the fund's prospectus (filed Jul 29, 2026).

IVOCX performance

Average annual total returns
1 yr5 yr10 yr
IVOCX+6.4%+7.3%+9.5%
Mid-Cap median+7.9%+8.1%+9.9%

Source: Fund prospectus, as of Dec 31, 2025

Full IVOCX performance history →

What IVOCX costs

On a $10,000 investment, IVOCX's 1.82% expense ratio costs about $182 a year. The prospectus estimates $2,351 in total costs over 10 years (assuming 5% annual returns). The median mid-cap fund charges 0.88%.

See the full IVOCX fee table →

IVOCX top 10 holdings

#Holding% of fund
1Arthur J. Gallagher & Company AJG3.03%
2First American Financial Corp FAF2.95%
3Service Corporation International SCI2.95%
4Sonoco Products Company SON2.92%
5Nvent Electric Plc NVT2.91%
6Quest Diagnostics Inc DGX2.91%
7Microchip Technology Inc MCHP2.90%
8Royalty Pharma Plc RPRX2.89%
9Paychex Inc PAYX2.89%
10Fastenal Company FAST2.88%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 29.2% of the fund. See all top 25 holdings and asset mix →

Alternatives to IVOCX

More funds like IVOCX →

IVOCX FAQ

What is the expense ratio of IVOCX?
IVOCX's expense ratio is 1.82%, which works out to about $182 a year for every $10,000 invested. The prospectus estimates total costs of $2,351 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is IVOCX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.82%); 12b-1 marketing fee of 1% a year. This is general information, not personalized advice.
What does IVOCX hold?
IVOCX's largest holdings are Arthur J. Gallagher & Company (3.0%), First American Financial Corp (3.0%), Service Corporation International (2.9%), Sonoco Products Company (2.9%), Nvent Electric Plc (2.9%). It holds 39 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is IVOCX's 5-year return?
IVOCX returned +7.3% a year over the five years ending Dec 31, 2025, and +9.5% a year over ten years. Past performance does not guarantee future results.
Does IVOCX have a sales load?
No. IVOCX has no front-end sales charge. It may charge a deferred sales charge of up to 1% if sold early.
Who manages IVOCX?
IVOCX is offered by Voya through Ivy Funds.